HC Wainwright Forecasts Altimmune’s Q1 Earnings (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT) – HC Wainwright increased their Q1 2026 EPS estimates for shares of Altimmune in a research note issued on Monday, March 16th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.23) per share for the quarter, up from their prior estimate of ($0.27). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Altimmune’s Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($0.97) EPS, Q1 2027 earnings at ($0.28) EPS, Q2 2027 earnings at ($0.30) EPS, Q3 2027 earnings at ($0.32) EPS, FY2027 earnings at ($1.20) EPS, FY2028 earnings at ($1.19) EPS, FY2029 earnings at ($0.79) EPS and FY2030 earnings at ($0.56) EPS.

Several other research firms have also weighed in on ALT. Wall Street Zen lowered shares of Altimmune from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Truist Financial initiated coverage on Altimmune in a research report on Wednesday. They issued a “buy” rating and a $12.00 target price on the stock. B. Riley Financial lowered their price target on Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a report on Friday, March 6th. Finally, Barclays initiated coverage on shares of Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Altimmune Stock Performance

Shares of ALT opened at $3.42 on Wednesday. Altimmune has a 12-month low of $2.90 and a 12-month high of $7.73. The firm has a market capitalization of $444.94 million, a P/E ratio of -3.39 and a beta of 0.13. The firm has a 50-day moving average price of $4.45 and a 200 day moving average price of $4.28. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.15.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.

Insiders Place Their Bets

In other news, Director John Gill bought 12,500 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The stock was bought at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the acquisition, the director directly owned 12,500 shares of the company’s stock, valued at $51,250. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jerome Benedict Durso bought 20,000 shares of the company’s stock in a transaction on Friday, March 6th. The stock was purchased at an average cost of $3.54 per share, with a total value of $70,800.00. Following the completion of the transaction, the chief executive officer owned 32,500 shares in the company, valued at $115,050. This represents a 160.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 55,527 shares of company stock valued at $213,778 over the last ninety days. Insiders own 4.40% of the company’s stock.

Institutional Trading of Altimmune

A number of large investors have recently modified their holdings of ALT. SBI Securities Co. Ltd. raised its position in Altimmune by 27.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock valued at $32,000 after purchasing an additional 1,928 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Altimmune by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after purchasing an additional 2,241 shares during the period. Concurrent Investment Advisors LLC increased its stake in Altimmune by 10.4% in the fourth quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock valued at $96,000 after purchasing an additional 2,500 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Altimmune by 10.9% in the second quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock valued at $108,000 after buying an additional 2,748 shares during the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of Altimmune by 4.0% in the fourth quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock valued at $289,000 after buying an additional 3,047 shares during the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Key Altimmune News

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Truist initiated coverage with a “Buy” rating and a $12.00 price target (roughly 250% upside vs. recent levels), which can attract new buyer interest and boost sentiment. Read More.
• Positive Sentiment: HC Wainwright reiterated a “Buy” stance and maintained a very high $25.00 target while raising several near‑term EPS forecasts (Q1–Q4 2026 and FY2026/FY2027 improvements), signaling better near‑term operating expectations and providing a bullish research narrative for investors. Read More.
• Neutral Sentiment: Short‑interest data published for March shows “0 shares” and NaN changes (days‑to‑cover reported as 0.0), which appears to be a reporting error. Because the numbers are unreliable, they are unlikely to be a meaningful trading signal until corrected.
• Neutral Sentiment: Multiple HC Wainwright model updates were issued: while near‑term quarterly and FY2026/FY2027 EPS forecasts were raised (positive), the firm also repriced longer‑range forecasts — creating mixed signals that may keep momentum uneven. Read More.
• Negative Sentiment: HC Wainwright trimmed FY2028 and FY2029 EPS estimates materially (FY2028 moved from ~(-$0.09) to about (-$1.19); FY2029 forecasts were cut sharply), reflecting weaker long‑range expectations that could limit upside beyond near‑term reactions. Read More.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.